First Patient Dosed in Ph III Trial of Bemarituzumab for Advanced Gastric and Gastroesophageal Junction Cancers

Five Prime Therapeutics, Inc. (Nasdaq: FPRX) and Zai Lab Limited (Nasdaq: ZLAB) announced on 10/1/18 dosing of the first patient in the Phase 3 FIGHT pivotal trial of bemarituzumab (FPA144), an isoform-selective FGF receptor 2b (FGFR2b) antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.